Anzupgo Cream
Product Images NDC 50222-280

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Anzupgo (NDC 50222-280). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Leo Pharma, Inc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure (Anzupgo 01)

Chemical structure diagram showing the molecular configuration of delgocitinib, the active ingredient in Anzupgo topical cream 20 mg/g by LEO Pharma, Inc.*

FDA Label Image

Figure 1 (Anzupgo 02)

A line graph showing the percentage of responders over a 16-week period comparing Delgocitinib 20 mg/g cream versus a vehicle. The graph tracks responders (%) on the Y-axis and weeks on the X-axis, illustrating higher response rates in the Delgocitinib group throughout the timeframe.*

FDA Label Image

Figure 1 (Anzupgo 03)

A line graph comparing responder percentages over 16 weeks between Delgocitinib 20 mg/g and vehicle groups. The x-axis represents weeks, and the y-axis shows the percentage of responders. The Delgocitinib group is marked with solid circles and a solid line, while the vehicle group uses open squares and a dashed line, indicating higher responder rates for Delgocitinib throughout the study.*

FDA Label Image

Figure 2 (Anzupgo 04)

A line graph comparing the percentage of responders over 16 weeks between Delgocitinib 20 mg/g cream (N=323) and a vehicle control (N=161). The x-axis represents weeks, and the y-axis represents the percentage of responders. The graph shows that the Delgocitinib group consistently has a higher response rate than the vehicle group throughout the study period.*

FDA Label Image

Figure 2 (Anzupgo 05)

A line graph comparing the percentage of responders over 16 weeks between Delgocitinib 20 mg/g cream and a vehicle control. The x-axis represents weeks from 0 to 16, and the y-axis represents the percentage of responders from 0% to 100%. The graph shows higher response rates for Delgocitinib compared to the vehicle throughout the study period.*

FDA Label Image

Figure 3 (Anzupgo 06)

A line graph comparing responder percentages over 16 weeks between delgocitinib 20 mg/g cream and vehicle. The x-axis shows weeks from 0 to 16, and the y-axis shows responder percentages from 0% to 90%. Delgocitinib shows a higher and increasing responder rate compared to the vehicle group.*

FDA Label Image

Figure 3 (Anzupgo 07)

A line graph depicting the percentage of responders over 16 weeks, comparing delgocitinib 20 mg/g cream to a vehicle control. The graph shows two lines: one for delgocitinib with a rising trend reaching around 50%, and one for the vehicle with a lower, gradual increase peaking near 25%. The x-axis represents time in weeks and the y-axis shows responder percentages.*

FDA Label Image

Principal Display Panel (30 g Tube Carton)

Box packaging label for Anzupgo (delgocitinib) cream 2%, 30 grams, a topical prescription drug by LEO Pharma, Inc. The label states the product is for topical use only and contains 20 mg of delgocitinib per gram of cream. Storage instructions and manufacturer/distributor information are included, along with a barcode and NDC 50222-280-30.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.